Stocks Health care CDNA
NASDAQ · Health careCareDx, Inc. (CDNA)
CareDx, Inc. brought in $497.4M of revenue over the twelve months to September 30, 2026, up 38.9% from a year earlier. Net income was $128.6M, a net margin of 25.9%. At September 30, 2026 it held $250.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about CareDx, Inc.
- Net worth
- CareDx, Inc. has a market value (market cap) of $4.4B at the latest share price, and shareholders' equity of $467.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $379.8M (+13.8% year on year), with a net loss of $21.4M. Over the 12 months to September 30, 2026: revenue $497.4M, net income $128.6M.
- Cash flow
- In fiscal 2025 operations brought in $42M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- CareDx, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What CareDx, Inc. does
CareDx, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker CDNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $379.8M | -$21.4M | -$0.40 | n/a |
| 2024 | $333.8M | $52.5M | $0.93 | n/a |
| 2023 | $280.3M | -$190.3M | -$3.54 | n/a |
| 2022 | $321.8M | -$76.6M | -$1.44 | n/a |
| 2021 | $296.4M | -$30.7M | -$0.59 | n/a |
| 2020 | $192.2M | -$18.7M | -$0.40 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CDNA ranks in Health care
Latest SEC filings
What CareDx, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 39% to $139.4M versus the same quarter last year; diluted EPS $0.35 versus $0.03.
- October 29, 2026
- September 16, 2026Acquisition or sale completed8-K/ACareDx filed an amended current report to provide historical financial statements and pro forma financial information for its acquisition of Naveris.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 52% to $131.9M versus the same quarter last year; diluted EPS $2.07 versus -$0.16.
- July 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running CareDx, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.8M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Novack Jeffrey AdamSecretary and General Counsel | Shares withheld for tax | 1,505 | $118.2K |
| November 5, 2026 | Kennedy KeithCFO & COO | Exercised options | 52,422 | $1.5M |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 28,256 | $2.2M |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 12,380 | $958.4K |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 6,897 | $542K |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 7,415 | $589.4K |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 3,403 | $273.5K |
| November 5, 2026 | Kennedy KeithCFO & COO | Soldpre-planned (10b5-1) | 2,710 | $220.6K |
Who owns CDNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bellevue Group AG13G, passive with 2 related filers | 5.9% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 227 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,814,709 | +292,613 |
| State Street Corp | 2,468,858 | -291,527 |
| Vanguard Capital Management LLC | 2,197,475 | +37,018 |
| Deerfield Management Company, L.P. | 1,997,618 | -193,382 |
| ARK Investment Management LLC | 1,953,531 | -274,025 |
| Boston Partners | 1,937,601 | +54,067 |
| Bamco Inc | 1,937,326 | -1,399,083 |
| Gagnon Securities LLC | 1,770,735 | +8,861 |
| Chevy Chase Trust Holdings, LLC | 1,437,416 | -66,659 |
| Geode Capital Management, LLC | 1,328,037 | +73,923 |
| Ophir Asset Management Pty Ltd | 1,264,809 | +276,758 |
| Renaissance Technologies LLC | 1,242,959 | +58,561 |
| Braidwell LP | 1,220,602 | -952,544 |
| First Eagle Investment Management, LLC | 1,196,994 | +621,629 |
| Sumitomo Mitsui Trust Group, Inc. | 1,191,630 | -283,496 |
| Blue Water Life Science Advisors, LP | 1,190,000 | +255,000 |
| Amova Asset Management Americas, Inc. | 1,188,075 | -287,051 |
| Dimensional Fund Advisors LP | 1,181,077 | -280,837 |
| D. E. Shaw & Co., Inc. | 1,137,660 | +262,752 |
| Jacobs Levy Equity Management, Inc | 995,669 | +131,201 |
Insiders
13 insiders reported holding 1,714,081 shares in total, about $144.7M at the last price.
| Holder | Shares |
|---|---|
| Hanna John Walter JRPresident and CEO, Director | 644,937 |
| Kennedy KeithCFO & COO | 199,147 |
| Meng JessicaChief Commercial Officer | 158,980 |
| Cohen Fred EDirector | 140,060 |
| Bickerstaff GeorgeDirector | 134,061 |
| Novack Jeffrey AdamSecretary and General Counsel | 100,700 |
| Smith NathanChief Financial Officer | 79,016 |
| Goldberg MichaelDirector | 62,326 |
| Cournoyer ChristineDirector | 42,943 |
| Riggsbee Richard BryanDirector | 39,312 |
Questions about CDNA
What does CareDx, Inc. do?
CareDx, Inc. is a company in the Health care sector, listed on NASDAQ as CDNA. Its shares trade on NASDAQ under the ticker CDNA.
What is CareDx, Inc.'s net worth?
CareDx, Inc. has a market value (market cap) of $4.4B at the latest share price, and shareholders' equity of $467.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CareDx, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $128.6M on revenue of $497.4M, a net margin of 25.9%.
How much revenue does CareDx, Inc. make?
Over the twelve months to September 30, 2026 CareDx, Inc. reported revenue of $497.4M. That is 38.9% more than a year earlier.
When did CareDx, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is CareDx, Inc.'s next earnings report?
CareDx, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CDNA with
Follow CDNA
Get an email when CareDx, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CareDx, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.